GUIDed Growth of the Proximal Femur to Prevent Further Hip MigrAtion in CErebral Palsy Patients

Status: Recruiting
Location: See all (5) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

In recent literature, the potential of guided growth of the proximal femur to modify hip growth in patients with cerebral palsy has been shown. Using medial hemi-epiphysiodesis of the proximal femur (TMH-PF) morphology of hips at risk of symptomatic (sub)luxation in cerebral palsy (CP) can be changed, aiming to reduce further hip migration and the need for more invasive surgical treatment modalities. Further research is necessary to assess if the results of TMH-PF in combination with adductor tenotomies are significantly better than the results of the current standard of care; adductor tenotomies alone. The investigators objective is to determine whether guided growth of the proximal femur decreases the risk of further hip migration and need for further surgery in cerebral palsy patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 2
Maximum Age: 8
Healthy Volunteers: f
View:

• Spastic CP

• GMFCS level IV-V

• Aged 2-8 years

• At least one hip with an abduction in flexion ≤ 40 degrees

• Migration percentage of 30-50%

• Head shaft angle \> 145

Locations
Other Locations
Netherlands
Amsterdam UMC
NOT_YET_RECRUITING
Amsterdam
UMC Groningen
RECRUITING
Groningen
Maastricht UMC
RECRUITING
Maastricht
Sint Maartenskliniek
NOT_YET_RECRUITING
Nijmegen
Erasmus MC
RECRUITING
Rotterdam
Contact Information
Primary
Merel Roelen, MD
m.roelen@erasmusmc.nl
+31639173455
Backup
Jaap Tolk, MD PhD
j.tolk@erasmusmc.nl
Time Frame
Start Date: 2024-03-06
Estimated Completion Date: 2030-12
Participants
Target number of participants: 84
Treatments
Experimental: Adductor tenotomy + Temporary Medial Hemi-epiphysiodesis of the proximal femur
Standard care + intervention
No_intervention: Adductor tenotomy
Standard care
Related Therapeutic Areas
Sponsors
Leads: Erasmus Medical Center

This content was sourced from clinicaltrials.gov